Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
ABMD's Cash-to-Debt is ranked higher than
99% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 2.36 vs. ABMD: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ABMD' s Cash-to-Debt Range Over the Past 10 Years
Min: 13.95  Med: No Debt Max: No Debt
Current: No Debt
13.95
No Debt
Equity-to-Asset 0.88
ABMD's Equity-to-Asset is ranked higher than
92% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. ABMD: 0.88 )
Ranked among companies with meaningful Equity-to-Asset only.
ABMD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.52  Med: 0.86 Max: 0.95
Current: 0.88
0.52
0.95
Debt-to-EBITDA 0.11
ABMD's Debt-to-EBITDA is ranked higher than
94% of the 158 Companies
in the Global Medical Devices industry.

( Industry Median: 2.02 vs. ABMD: 0.11 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ABMD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.11  Med: 0.17 Max: 0.17
Current: 0.11
0.11
0.17
Piotroski F-Score: 6
Altman Z-Score: 83.83
Beneish M-Score: -2.57
WACC vs ROIC
3.86%
30.44%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 25.47
ABMD's Operating Margin % is ranked higher than
93% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 1.96 vs. ABMD: 25.47 )
Ranked among companies with meaningful Operating Margin % only.
ABMD' s Operating Margin % Range Over the Past 10 Years
Min: -61.9  Med: 2.88 Max: 25.47
Current: 25.47
-61.9
25.47
Net Margin % 16.59
ABMD's Net Margin % is ranked higher than
86% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 1.42 vs. ABMD: 16.59 )
Ranked among companies with meaningful Net Margin % only.
ABMD' s Net Margin % Range Over the Past 10 Years
Min: -69.44  Med: 2.59 Max: 49.36
Current: 16.59
-69.44
49.36
ROE % 16.87
ABMD's ROE % is ranked higher than
87% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.48 vs. ABMD: 16.87 )
Ranked among companies with meaningful ROE % only.
ABMD' s ROE % Range Over the Past 10 Years
Min: -37.95  Med: 3.05 Max: 49.44
Current: 16.87
-37.95
49.44
ROA % 14.47
ABMD's ROA % is ranked higher than
92% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: -0.20 vs. ABMD: 14.47 )
Ranked among companies with meaningful ROA % only.
ABMD' s ROA % Range Over the Past 10 Years
Min: -32.2  Med: 2.49 Max: 41.81
Current: 14.47
-32.2
41.81
ROC (Joel Greenblatt) % 108.03
ABMD's ROC (Joel Greenblatt) % is ranked higher than
94% of the 328 Companies
in the Global Medical Devices industry.

( Industry Median: 3.76 vs. ABMD: 108.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ABMD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -206.12  Med: 28.38 Max: 171.62
Current: 108.03
-206.12
171.62
3-Year Revenue Growth Rate 31.20
ABMD's 3-Year Revenue Growth Rate is ranked higher than
92% of the 256 Companies
in the Global Medical Devices industry.

( Industry Median: 4.00 vs. ABMD: 31.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ABMD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -30.6  Med: 14.4 Max: 51.9
Current: 31.2
-30.6
51.9
3-Year EBITDA Growth Rate 102.20
ABMD's 3-Year EBITDA Growth Rate is ranked higher than
97% of the 235 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. ABMD: 102.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ABMD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -56  Med: 12.85 Max: 136.2
Current: 102.2
-56
136.2
3-Year EPS without NRI Growth Rate 86.60
ABMD's 3-Year EPS without NRI Growth Rate is ranked higher than
96% of the 228 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. ABMD: 86.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ABMD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -57.8  Med: 18.6 Max: 304.6
Current: 86.6
-57.8
304.6
GuruFocus has detected 4 Warning Signs with Abiomed Inc ABMD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ABMD's 30-Y Financials

Financials (Next Earnings Date: 2018-05-04)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

ABMD Guru Trades in Q1 2017

George Soros 2,400 sh (New)
Chuck Royce 17,000 sh (+70.00%)
Jim Simons 668,700 sh (+27.64%)
Columbia Wanger Sold Out
PRIMECAP Management 4,636,590 sh (-0.86%)
Steven Cohen 56,700 sh (-38.77%)
» More
Q2 2017

ABMD Guru Trades in Q2 2017

Jim Simons 893,223 sh (+33.58%)
Chuck Royce 20,000 sh (+17.65%)
Steven Cohen Sold Out
George Soros Sold Out
PRIMECAP Management 4,434,088 sh (-4.37%)
» More
Q3 2017

ABMD Guru Trades in Q3 2017

Jim Simons 1,088,424 sh (+21.85%)
Chuck Royce 20,000 sh (unchged)
PRIMECAP Management 4,217,890 sh (-4.88%)
» More
Q4 2017

ABMD Guru Trades in Q4 2017

Joel Greenblatt 5,297 sh (New)
Pioneer Investments 65,028 sh (New)
Lee Ainslie 32,580 sh (New)
Jim Simons 1,082,723 sh (-0.52%)
PRIMECAP Management 4,079,390 sh (-3.28%)
Chuck Royce 10,000 sh (-50.00%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ABMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-12-31 New Buy0.01%$168.78 - $199.74 $ 268.2544%5,297
George Soros 2017-06-30 Sold Out 0.01%$120.73 - $145.94 $ 268.25100%0
George Soros 2017-03-31 New Buy0.01%$104.1 - $125.26 $ 268.25131%2,400
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:XSWX:SOON, NYSE:VAR, NYSE:TFX, OCSE:WDH, ASX:COH, SZSE:300003, XPAR:DIM, LSE:SN., LSE:CTEC, NZSE:FPH, NAS:MASI, NYSE:GMED, OCSE:AMBU B, OCSE:GN, NAS:LIVN, NAS:IART, HKSE:01066, OSTO:EKTA B, NYSE:PEN, SZSE:002223 » details
Traded in other countries:AIO.Germany,
Headquarter Location:USA
Abiomed Inc is a medical device company. It provides mechanical circulatory support devices to aid heart recovery to heart failure patients.

Abiomed provides temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons. The firm's products are primarily used for patients in need of hemodynamic support before, during, or after angioplasty and heart surgery procedures. They work by improving blood flow to coronary arteries or temporarily performing the pumping function of the heart. Abiomed receives the majority of revenue from its Impella product portfolio, which includes percutaneous micro heart pumps with integration motors and sensors and percutaneous catheter-based axial flow pumps. Abiomed generates the majority of its revenue in the United States.

Top Ranked Articles about Abiomed Inc

Abiomed Receives Approval for Expanded FDA Indication for High Risk Percutaneous Coronary Intervention (PCI) Procedures
Abiomed Announces Peripartum and Postpartum Cardiomyopathy Approval and Women’s Initiative for Heart Recovery
Abiomed Third Quarter Fiscal 2018 Earnings and Conference Call Notification
Abiomed Third Quarter Fiscal 2018 Earnings and Conference Call Notification
Detailed Research: Economic Perspectives on ABIOMED, NetScout, FTI Consulting, Enova International, Sturm, Ruger, and IDEX — What Drives Growth in Today's Competitive Landscape
Abiomed Announces Preliminary Q3 FY 2018 Revenue of $154 Million, Up 34% Over Prior Year
Abiomed to Present at the 36th Annual J.P. Morgan Healthcare Conference
Abiomed to Present at the 36th Annual J.P. Morgan Healthcare Conference
6 Stocks That Are Outperforming the Market Accenture, Adove among companies that have beated the S&P 500 over the past year
According to GuruFocus' All-in-One Guru Screener, the following are some of the stocks that have outperformed the Standard & Poor's 500 Index over the last 12 months and were bought by gurus during the last quarter. Read more...
Abiomed Announces First Patient Treated with Impella® in Japan

Ratios

vs
industry
vs
history
PE Ratio 134.80
ABMD's PE Ratio is ranked lower than
94% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 28.67 vs. ABMD: 134.80 )
Ranked among companies with meaningful PE Ratio only.
ABMD' s PE Ratio Range Over the Past 10 Years
Min: 22.02  Med: 97.85 Max: 615.5
Current: 134.8
22.02
615.5
PE Ratio without NRI 134.80
ABMD's PE Ratio without NRI is ranked lower than
94% of the 180 Companies
in the Global Medical Devices industry.

( Industry Median: 28.67 vs. ABMD: 134.80 )
Ranked among companies with meaningful PE Ratio without NRI only.
ABMD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 22.02  Med: 97.85 Max: 615.5
Current: 134.8
22.02
615.5
Price-to-Owner-Earnings 106.58
ABMD's Price-to-Owner-Earnings is ranked lower than
81% of the 103 Companies
in the Global Medical Devices industry.

( Industry Median: 35.70 vs. ABMD: 106.58 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ABMD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 44.38  Med: 96.58 Max: 201.19
Current: 106.58
44.38
201.19
PB Ratio 18.76
ABMD's PB Ratio is ranked lower than
93% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 2.85 vs. ABMD: 18.76 )
Ranked among companies with meaningful PB Ratio only.
ABMD' s PB Ratio Range Over the Past 10 Years
Min: 1.58  Med: 5.9 Max: 19.04
Current: 18.76
1.58
19.04
PS Ratio 22.45
ABMD's PS Ratio is ranked lower than
89% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.19 vs. ABMD: 22.45 )
Ranked among companies with meaningful PS Ratio only.
ABMD' s PS Ratio Range Over the Past 10 Years
Min: 2.38  Med: 6.62 Max: 22.79
Current: 22.45
2.38
22.79
Price-to-Free-Cash-Flow 119.00
ABMD's Price-to-Free-Cash-Flow is ranked lower than
92% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 31.00 vs. ABMD: 119.00 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ABMD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 23.56  Med: 65.1 Max: 1172.38
Current: 119
23.56
1172.38
Price-to-Operating-Cash-Flow 70.45
ABMD's Price-to-Operating-Cash-Flow is ranked lower than
92% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 20.56 vs. ABMD: 70.45 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ABMD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 21.72  Med: 52.42 Max: 430.93
Current: 70.45
21.72
430.93
EV-to-EBIT 83.56
ABMD's EV-to-EBIT is ranked lower than
91% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 24.04 vs. ABMD: 83.56 )
Ranked among companies with meaningful EV-to-EBIT only.
ABMD' s EV-to-EBIT Range Over the Past 10 Years
Min: -305.5  Med: 40.5 Max: 694.7
Current: 83.56
-305.5
694.7
EV-to-EBITDA 78.04
ABMD's EV-to-EBITDA is ranked lower than
94% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 18.40 vs. ABMD: 78.04 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABMD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -397.6  Med: 45.3 Max: 727.3
Current: 78.04
-397.6
727.3
EV-to-Revenue 21.29
ABMD's EV-to-Revenue is ranked lower than
85% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 3.64 vs. ABMD: 21.29 )
Ranked among companies with meaningful EV-to-Revenue only.
ABMD' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.7  Med: 6.2 Max: 22
Current: 21.29
1.7
22
PEG Ratio 2.00
ABMD's PEG Ratio is ranked higher than
60% of the 75 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ABMD: 2.00 )
Ranked among companies with meaningful PEG Ratio only.
ABMD' s PEG Ratio Range Over the Past 10 Years
Min: 1.16  Med: 1.44 Max: 2
Current: 2
1.16
2
Shiller PE Ratio 584.90
ABMD's Shiller PE Ratio is ranked lower than
96% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 47.20 vs. ABMD: 584.90 )
Ranked among companies with meaningful Shiller PE Ratio only.
ABMD' s Shiller PE Ratio Range Over the Past 10 Years
Min: 377.65  Med: 626.73 Max: 12369
Current: 584.9
377.65
12369
Current Ratio 5.60
ABMD's Current Ratio is ranked higher than
83% of the 329 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. ABMD: 5.60 )
Ranked among companies with meaningful Current Ratio only.
ABMD' s Current Ratio Range Over the Past 10 Years
Min: 3.18  Med: 6.69 Max: 32.71
Current: 5.6
3.18
32.71
Quick Ratio 4.98
ABMD's Quick Ratio is ranked higher than
86% of the 329 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. ABMD: 4.98 )
Ranked among companies with meaningful Quick Ratio only.
ABMD' s Quick Ratio Range Over the Past 10 Years
Min: 2  Med: 5.56 Max: 31.29
Current: 4.98
2
31.29
Days Inventory 159.27
ABMD's Days Inventory is ranked lower than
59% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 141.33 vs. ABMD: 159.27 )
Ranked among companies with meaningful Days Inventory only.
ABMD' s Days Inventory Range Over the Past 10 Years
Min: 138.81  Med: 154.05 Max: 314.91
Current: 159.27
138.81
314.91
Days Sales Outstanding 43.52
ABMD's Days Sales Outstanding is ranked higher than
86% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 66.85 vs. ABMD: 43.52 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABMD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.52  Med: 54.23 Max: 87.14
Current: 43.52
43.52
87.14
Days Payable 91.48
ABMD's Days Payable is ranked higher than
69% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 61.22 vs. ABMD: 91.48 )
Ranked among companies with meaningful Days Payable only.
ABMD' s Days Payable Range Over the Past 10 Years
Min: 60.98  Med: 97.03 Max: 218.64
Current: 91.48
60.98
218.64

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.00
ABMD's 3-Year Average Share Buyback Ratio is ranked higher than
59% of the 247 Companies
in the Global Medical Devices industry.

( Industry Median: -5.70 vs. ABMD: -3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABMD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.9  Med: -4.8 Max: -0.5
Current: -3
-14.9
-0.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 55.42
ABMD's Price-to-Net-Cash is ranked lower than
85% of the 101 Companies
in the Global Medical Devices industry.

( Industry Median: 13.00 vs. ABMD: 55.42 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ABMD' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.29  Med: 11.13 Max: 73.96
Current: 55.42
1.29
73.96
Price-to-Net-Current-Asset-Value 35.44
ABMD's Price-to-Net-Current-Asset-Value is ranked lower than
89% of the 211 Companies
in the Global Medical Devices industry.

( Industry Median: 7.36 vs. ABMD: 35.44 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ABMD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.08  Med: 7.16 Max: 35.97
Current: 35.44
1.08
35.97
Price-to-Tangible-Book 20.43
ABMD's Price-to-Tangible-Book is ranked lower than
89% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. ABMD: 20.43 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ABMD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1  Med: 5.43 Max: 20.74
Current: 20.43
1
20.74
Price-to-Intrinsic-Value-Projected-FCF 9.75
ABMD's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
85% of the 122 Companies
in the Global Medical Devices industry.

( Industry Median: 2.37 vs. ABMD: 9.75 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ABMD' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 4.39  Med: 7.13 Max: 163.8
Current: 9.75
4.39
163.8
Price-to-Median-PS-Value 3.39
ABMD's Price-to-Median-PS-Value is ranked lower than
96% of the 239 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. ABMD: 3.39 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ABMD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.34  Med: 1.11 Max: 6.39
Current: 3.39
0.34
6.39
Price-to-Peter-Lynch-Fair-Value 5.39
ABMD's Price-to-Peter-Lynch-Fair-Value is ranked lower than
91% of the 45 Companies
in the Global Medical Devices industry.

( Industry Median: 1.96 vs. ABMD: 5.39 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ABMD' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 2.31  Med: 3.77 Max: 35.22
Current: 5.39
2.31
35.22
Price-to-Graham-Number 11.06
ABMD's Price-to-Graham-Number is ranked lower than
94% of the 136 Companies
in the Global Medical Devices industry.

( Industry Median: 2.11 vs. ABMD: 11.06 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ABMD' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.99  Med: 6.22 Max: 15.52
Current: 11.06
2.99
15.52
Earnings Yield (Greenblatt) % 1.19
ABMD's Earnings Yield (Greenblatt) % is ranked higher than
53% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. ABMD: 1.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ABMD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -24  Med: 0.8 Max: 3.7
Current: 1.19
-24
3.7
Forward Rate of Return (Yacktman) % 71.29
ABMD's Forward Rate of Return (Yacktman) % is ranked higher than
98% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 6.87 vs. ABMD: 71.29 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ABMD' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -40.8  Med: 0.7 Max: 77.9
Current: 71.29
-40.8
77.9

More Statistics

Revenue (TTM) (Mil) $543.99
EPS (TTM) $ 1.99
Beta0.16
Short Percentage of Float2.38%
52-Week Range $114.28 - 273.27
Shares Outstanding (Mil)44.28

Analyst Estimate

Mar18
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) 2.06
EPS without NRI ($) 2.06
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}